Nucleus Network has recently opened its expanded facility in Sydney for Phase I clinical trials. Credit: Nucleus Network. There is no denying that Australia hits above its weight class in early ...

Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.

Finding an antibody with an attractive predicted binding score is only the start of discovery. Biopharmaceutical teams must establish whether a candidate can be produced, binds selectively and ...

Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of Zalsupindole, an orally bioavailable neuroplastogen.

CRL has signed definitive agreements to acquire Frontage’s bioanalysis and DMPK operations in Exton, Pennsylvania for roughly $470m in cash.

Network Bio has entered into a research collaboration with Duke University to develop AI models of human disease using biospecimens and clinical records.

Lonza’s deal to acquire almost all of Merck KGaA’s US CDMO network will significantly boost its US footprint and capabilities in key areas.

The US Food and Drug Administration (FDA) has authorised Johnson & Johnson’s (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain patients with head and neck ...

The MHRA is hoping to listen to a diverse range of voices to guide its regulatory strategy. Credit: Pressmaster / Shutterstock.com. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of $750m.

Alfasigma has received the EC's expanded approval for Jyseleca to treat adult patients living with active axial spondyloarthritis (axSpA).